CoChat

Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines

Open access

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Abstract

Global vaccination programs using live-attenuated oral and inactivated polio vaccine (OPV and IPV) have almost eradicated poliovirus (PV) but these vaccines or their production pose significant risk in a polio-free world. Recombinant PV virus-like particles (VLPs), lacking the viral genome, represent safe next-generation vaccines, however their production requires optimisation. Here we present an efficient mammalian expression strategy producing good yields of wild-type PV VLPs for all three serotypes and a thermostabilised variant for PV3. Whilst the wild-type VLPs were predominantly in the non-native C-antigenic form, the thermostabilised PV3 VLPs adopted the native D-antigenic conformation eliciting neutralising antibody titres equivalent to the current IPV and were indistinguishable from natural empty particles by cryo-electron microscopy with a similar stabilising lipidic pocket-factor in the VP1 β-barrel. This factor may not be available in alternative expression systems, which may require synthetic pocket-binding factors. VLPs equivalent to these mammalian expressed thermostabilized particles, represent safer non-infectious vaccine candidates for the post-eradication era.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41541-020-00267-3

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The poliovirus genome and expression cassettes designed to test P1 and 3CD* co-expression. a Schematic representation of the poliovirus genome highlighting the P1 region and individual capsid protein subunits generated from proteolytic processing by 3CD. b Format of the three separate expression cassettes used to test co-expression of P1 and 3CD* in PV1 wt (FMDV-2A), PV2 wt (HIV-FS) and PV3 wt (PV-IRES). Image was created using SnapGene® software (from GSL Biotech; available at snapgene.com).
Fig. 1 The poliovirus genome and expression cassettes designed to test P1 and 3CD* co-expression. a Schematic representation of the poliovirus genome highlighting the P1 region and individual capsid protein subunits generated from proteolytic processing by 3CD. b Format of the three separate expression cassettes used to test co-expression of P1 and 3CD* in PV1 wt (FMDV-2A), PV2 wt (HIV-FS) and PV3 wt (PV-IRES). Image was created using SnapGene® software (from GSL Biotech; available at snapgene.com).CC BY · PubMed Central
Fig. 2 Small-scale expression of MVA-PV1 and MVA-PV3 constructs to determine optimum parameters for large-scale infection/expression. a, b Western blots of 6-well screens for MVA-PV1_FMDV-2A (a) and MVA-PV3_PV-IRES (b) co-infected with MVA-T7 to test optimum MOI ratios for expression. MOI ratios tested in each lane are shown above the blot for MVA-T7 and either MVA-PV1_FMDV-2A (MVA-PV1, a) or MVA-PV3_PV-IRES (MVA-PV3, b). c, d Western blots of MVA-PV1_FMDV-2A (c) and MVA-PV3_PV-IRES (d) co-infected with MVA-T7 at their optimum MOIs determined from (a) and (b) to test temperature (30 °C and 37 °C) and time point of harvest (12–72 h, in 12 h time points). Detection was with anti-poliovirus blend of monoclonal antibodies MAB8566 (Millipore).
Fig. 2 Small-scale expression of MVA-PV1 and MVA-PV3 constructs to determine optimum parameters for large-scale infection/expression. a, b Western blots of 6-well screens for MVA-PV1_FMDV-2A (a) and MVA-PV3_PV-IRES (b) co-infected with MVA-T7 to test optimum MOI ratios for expression. MOI ratios tested in each lane are shown above the blot for MVA-T7 and either MVA-PV1_FMDV-2A (MVA-PV1, a) or MVA-PV3_PV-IRES (MVA-PV3, b). c, d Western blots of MVA-PV1_FMDV-2A (c) and MVA-PV3_PV-IRES (d) co-infected with MVA-T7 at their optimum MOIs determined from (a) and (b) to test temperature (30 °C and 37 °C) and time point of harvest (12–72 h, in 12 h time points). Detection was with anti-poliovirus blend of monoclonal antibodies MAB8566 (Millipore).CC BY · PubMed Central
Fig. 3 Expansion of expression screen using transient assay. a, b Western blot analysis of lysates from GMK cells infected with MVA-T7 and transfected in triplicates with pMVA-PV1_FMDV-2A, pMVA-PV1_PV-IRES, pMVA-PV3_FMDV-2A, pMVA-PV3_PV-IRES (panel a) and pMVA-PV2_HIV-FS, pMVA-PV2_PV-IRES or mock-transfected (panel b). Detection was via anti-poliovirus blend of monoclonal antibodies MAB8566 (Millipore).
Fig. 3 Expansion of expression screen using transient assay. a, b Western blot analysis of lysates from GMK cells infected with MVA-T7 and transfected in triplicates with pMVA-PV1_FMDV-2A, pMVA-PV1_PV-IRES, pMVA-PV3_FMDV-2A, pMVA-PV3_PV-IRES (panel a) and pMVA-PV2_HIV-FS, pMVA-PV2_PV-IRES or mock-transfected (panel b). Detection was via anti-poliovirus blend of monoclonal antibodies MAB8566 (Millipore).CC BY · PubMed Central
Fig. 4 Expression and characterisation of wild-type VLPs for PV1, PV2 and PV3 produced in PV-IRES cassette. a–c Western blot of fractions from sucrose gradient purified wt VLPs of PV1 (a), PV2 (b) and PV3 (c) expressed using the PV-IRES cassette. Gradients are fractionated from top (fraction 1) to bottom (fraction 12). Detection was with anti-poliovirus blend of monoclonal antibodies MAB8566 (Millipore). d Coomassie stained gel of pooled, desalted and concentrated peak fractions for PV1 wt, PV2 wt and PV3 wt identified in a–c. Protein bands for individual subunits VP0 (37.5 kDa), VP1 (33.1 kDa) and VP3 (26.5 kDa) are labelled. e-g Negative stain EM images of PV1 wt, PV2 wt and PV3 wt VLPs produced from the PV-IRES expression cassette. Black arrowheads highlight individual VLPs. Scale bars 100 nm.
Fig. 4 Expression and characterisation of wild-type VLPs for PV1, PV2 and PV3 produced in PV-IRES cassette. a–c Western blot of fractions from sucrose gradient purified wt VLPs of PV1 (a), PV2 (b) and PV3 (c) expressed using the PV-IRES cassette. Gradients are fractionated from top (fraction 1) to bottom (fraction 12). Detection was with anti-poliovirus blend of monoclonal antibodies MAB8566 (Millipore). d Coomassie stained gel of pooled, desalted and concentrated peak fractions for PV1 wt, PV2 wt and PV3 wt identified in a–c. Protein bands for individual subunits VP0 (37.5 kDa), VP1 (33.1 kDa) and VP3 (26.5 kDa) are labelled. e-g Negative stain EM images of PV1 wt, PV2 wt and PV3 wt VLPs produced from the PV-IRES expression cassette. Black arrowheads highlight individual VLPs. Scale bars 100 nm.CC BY · PubMed Central
Fig. 5 The antigenicity profile of wt VLPs for PV1, PV2 and PV3 as assessed by ELISA using monoclonal antibodies specific for either native (D) or non-native (C) conformations. a–c D and C-antigenicity of PV1 wt, PV2 wt and PV3 wt VLPs and IPV control respectively. Monoclonal antibodies used for detection were: 234 for PV1, 1050 for PV2 and 520 for PV3 (D-antigen specific) and 1588 for PV1 and 517 for PV3 (C-antigen specific). There was no C-antigen specific antibody available for PV2 wt.
Fig. 5 The antigenicity profile of wt VLPs for PV1, PV2 and PV3 as assessed by ELISA using monoclonal antibodies specific for either native (D) or non-native (C) conformations. a–c D and C-antigenicity of PV1 wt, PV2 wt and PV3 wt VLPs and IPV control respectively. Monoclonal antibodies used for detection were: 234 for PV1, 1050 for PV2 and 520 for PV3 (D-antigen specific) and 1588 for PV1 and 517 for PV3 (C-antigen specific). There was no C-antigen specific antibody available for PV2 wt.CC BY · PubMed Central
Fig. 6 Antigenicity and thermostability of the stabilised PV3 SC8 VLP. a D or C-antigen reactivity of PV3 SC8 VLP or IPV assessed by ELISA. b Reactivity of PV3 SC8 VLP and IPV aliquots to D-antigen specific MAb 520 in ELISA after incubation at different temperatures for 10 minutes, normalised to corresponding aliquot incubated at 4 °C.
Fig. 6 Antigenicity and thermostability of the stabilised PV3 SC8 VLP. a D or C-antigen reactivity of PV3 SC8 VLP or IPV assessed by ELISA. b Reactivity of PV3 SC8 VLP and IPV aliquots to D-antigen specific MAb 520 in ELISA after incubation at different temperatures for 10 minutes, normalised to corresponding aliquot incubated at 4 °C.CC BY · PubMed Central
Fig. 7 Immunogenicity of stabilised PV3 SC8 VLPs in Rats. Geometric mean neutralising antibody titres of sera from rats inoculated with a dilution series of PV3 SC8 VLPs or IPV. Bars indicate geometric standard deviation.
Fig. 7 Immunogenicity of stabilised PV3 SC8 VLPs in Rats. Geometric mean neutralising antibody titres of sera from rats inoculated with a dilution series of PV3 SC8 VLPs or IPV. Bars indicate geometric standard deviation.CC BY · PubMed Central
Fig. 8 Cryo-EM structure analysis of the stabilised PV3 SC8 VLP. a Cryo-electron micrograph of PV3 SC8 VLPs embedded in vitreous ice. Scale bar 50 nm. b Cryo-EM map of the PV3 SC8 reconstruction coloured by radius from red to blue according to the scale bar shown. Representative 5-fold, 3-fold and 2-fold axes are indicated. The outer diameter of the particle is ~300 Å. c Electron potential map for the PV3 SC8 VP1 pocket showing the bound sphingosine-like molecule (orange) and surrounding residues of VP1 (green); key residues interacting with the modelled sphingosine are labelled. Electron potential is contoured at 1.0 σ and rendered at a radius of 2 Å around atoms. d Individual panels showing the cryo-EM density for the stabilising mutations introduced into the PV3 SC8 VLP. Residue numbering is equivalent to the mature capsid proteins VP1, VP2 and VP3. VP4 T67A was disordered. Electron potential is contoured at 1.0 σ and rendered at a radius of 2 Å around atoms.
Fig. 8 Cryo-EM structure analysis of the stabilised PV3 SC8 VLP. a Cryo-electron micrograph of PV3 SC8 VLPs embedded in vitreous ice. Scale bar 50 nm. b Cryo-EM map of the PV3 SC8 reconstruction coloured by radius from red to blue according to the scale bar shown. Representative 5-fold, 3-fold and 2-fold axes are indicated. The outer diameter of the particle is ~300 Å. c Electron potential map for the PV3 SC8 VP1 pocket showing the bound sphingosine-like molecule (orange) and surrounding residues of VP1 (green); key residues interacting with the modelled sphingosine are labelled. Electron potential is contoured at 1.0 σ and rendered at a radius of 2 Å around atoms. d Individual panels showing the cryo-EM density for the stabilising mutations introduced into the PV3 SC8 VLP. Residue numbering is equivalent to the mature capsid proteins VP1, VP2 and VP3. VP4 T67A was disordered. Electron potential is contoured at 1.0 σ and rendered at a radius of 2 Å around atoms.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Research works printed but not linked: 1

  1. Racaniello, V. R. In Fields virology (eds David M. Knipe & Peter M. Howley) 453–489 (Wolters Kluwer/Lippincott Williams & Wilkins Health, 2013).

Cited by

See all 43

Metadata

Authors
Bahar, M. W., Porta, C., Fox, H., Macadam, A. J., Fry, E. E., & Stuart, D. I.
Affiliations
  • University of Oxford (GB)
  • The Pirbright Institute (GB)
  • National Institute for Biological Standards and Control (GB)
  • Diamond Light Source (GB)
Corresponding author
  • Bahar, Mohammad W.
  • Stuart, David I.
Venue
npj Vaccines
Published
2021-01-08
Volume
6
Issue
1
Pages
5-5
ISSN
2059-0105 (ISSN-L)
OpenAlex
W3118614350
Cited by
42
References
71
Citations by year
2026: 6 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 8
FWCI
2.20
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Vaccines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Defra | Animal Health and Veterinary Laboratories Agency (SE2815)
  • DEFRA
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
Keywords
poliovirus, virus-like particles, mammalian expression, poliovirus serotypes, neutralizing antibodies, vaccine safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. https://app.cochat.ai/papers/10.1038/s41541-020-00267-3
The paper
Bahar, M. W., Porta, C., Fox, H., Macadam, A. J., Fry, E. E., & Stuart, D. I. (2021). Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. npj Vaccines. https://doi.org/10.1038/s41541-020-00267-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.